Fulcrum Therapeutics Inc [FULC] stock prices are up 0.19% to $10.38 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The FULC shares have gain 2.67% over the last week, with a monthly amount drifted -19.66%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Fulcrum Therapeutics Inc [NASDAQ: FULC] stock has seen the most recent analyst activity on January 12, 2026, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $20. On July 29, 2025, upgrade upgraded it’s rating to Buy and revised its price target to $12 on the stock. Leerink Partners upgraded its rating to a Outperform but stick to its price target of $12 on May 23, 2025. Cantor Fitzgerald upgraded its rating to a Overweight but $10 remained the price target by the analyst firm on May 15, 2025. H.C. Wainwright downgraded its rating to Neutral for this stock on September 13, 2024, and downed its price target to $4. In a note dated September 12, 2024, Stifel downgraded an Hold rating on this stock.
The stock price of Fulcrum Therapeutics Inc [FULC] has been fluctuating between $2.32 and $15.74 over the past year. Currently, Wall Street analysts expect the stock to reach $20.71 within the next 12 months. Fulcrum Therapeutics Inc [NASDAQ: FULC] shares were valued at $10.38 at the most recent close of the market. An investor can expect a potential return of 99.52% based on the average FULC price forecast.
Analyzing the FULC fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.32 and Total Capital is -0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Fulcrum Therapeutics Inc [NASDAQ:FULC]’s Current Ratio is 17.70. As well, the Quick Ratio is 17.70, while the Cash Ratio is 4.05.
Transactions by insiders
Recent insider trading involved Gould Robert J, Director, that happened on Jan 02 ’26 when 15000.0 shares were sold. Chief Legal Officer, Oltmans Curtis Gale completed a deal on Dec 15 ’25 to sell 3452.0 shares. Meanwhile, Officer CURTIS G OLTMANS bought 3452.0 shares on Dec 15 ’25.
